C 029: NEW PROMISING CANDIDATES FOR DIABETES TYPE 2 TREATMENTS OBTAINED FROM NATURAL SOURCES

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S84, 2014 Special supplement with the abstract book of LATINFARMA 2013 Conference C 029: NEW PROMISING CANDIDATES FOR DIABETES TYPE 2 TREATMENTS OBTAINED FROM NATURAL SOURCES: INHIBITORY EFFECTS ON PTP1B, DPPIV AND GLUCOSE UPTAKE IN VITRO ASSAY Marrero Faz E1, Sánchez Calero E1, Young L2 and Harvey A.2 1Grupo … Continue reading C 029: NEW PROMISING CANDIDATES FOR DIABETES TYPE 2 TREATMENTS OBTAINED FROM NATURAL SOURCES

J Pharm Pharmacogn Res 2(Suppl. 1): S84, 2014

Special supplement with the abstract book of LATINFARMA 2013

Conference

C 029: NEW PROMISING CANDIDATES FOR DIABETES TYPE 2 TREATMENTS OBTAINED FROM NATURAL SOURCES: INHIBITORY EFFECTS ON PTP1B, DPPIV AND GLUCOSE UPTAKE IN VITRO ASSAY

Marrero Faz E1, Sánchez Calero E1, Young L2 and Harvey A.2

1Grupo de Desarrollo Biofarmacéutico, Centro Nacional de Sanidad Agropecuaria (CENSA), Mayabeque, Cuba. E-mail: eva.marrero@infomed.sld.cu
2Strathclyde Institute for Biomedical Sciences, Strahclyde University, Scotland, United Kingdom.
Abstract

The present study is aimed to determine the underlying mechanism of the antidiabetic efficacy of seven medicinal Cuban plants: Allophylus cominia (L.) Sw., Ocimum tenuiflorum, Persea americana, Sechium edule green and white varieties, Momordica charantia and Jatropha aethiopica, some of them reported in Cuban ethnomedicine. The aqueous extracts from these plants and their fractions were evaluated on type 2 diabetes therapeutic targets: protein tyrosine phosphatase 1B (PTP1B) and dipeptidyl peptidase-IV (DPPIV) enzymatic activities and glucose uptake, in order to identify the candidate plants that can be used more effectively in treating diabetes. All in vitro assays were performed on 96 micro well plates. In PTP1B enzymatic assay (6, 8-difluoro-4-methylumbelliferyl phosphate) (DiFMUP) was used as substrate and as standard inhibitor [Bis(4-Trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzine] (TFMS); in DPPIV enzymatic assay [Gly-Pro-7-amido-4-methylcoumarin hydrobromide] (Gly-proAMC) was used as substrate and as standard inhibitor [(3N-[(2S, 3S)-2amino-3-methyl-pentanoyl]-1,3-thiazolidine) hemifumarate] (P32/98); in both assays, the enzymatic activity inhibition was calculated with the fluorescence values using an excitation wavelength of 360 nm and an emission wavelength of 460 nm. Glucose uptake studies were performed on fully differentiated 3T3-L1 adipocytes using 2-deoxy-D[3H] glucose and insulin as a positive control, the radioactivity incorporated into the cells was measured with a microplate scintillation counter. The results revealed that only aqueous extracts from A cominia, O tenuiflorum and P americana inhibited the enzymatic activity of PTP1B in an extract concentration dependent manner, resulting more active the more polar fractions from A. cominia and P. americana extracts and fraction 2 from O. tenuiflorum extract. All the extracts and fractions showed only a slight inhibition of enzymatic activity of DPPIV, at higher concentrations, A cominia aqueous extract also inhibited the enzymatic activity of this protease in an extract concentration dependent manner, only fraction 1 from P americana aqueous extract showed a moderate inhibitory effect. A. cominia, O. tenuiflorum and P. americana extracts exhibited a moderate enhance of glucose uptake in 3T3-L1 adipocytes, resulting more active fractions 6 and 10 from A. cominia extract and fraction 10 from P. americana extract. The present research demonstrated that aqueous extracts from A. cominia, P. americana and O. tenuiflorum and some of its fractions (AcF6, AcF10 and PaF10), are promising candidates for the development of antidiabetic phytopharmaceuticals and for drug discovery issues as well. Further research will be necessary in order to explore new molecular targets related with this metabolic disorder, such as: biomarkers of carbohydrates and lipids metabolism as well as to identify the secondary metabolites responsible of antidiabetic activity.

Piceatannol-rich extract from Passiflora edulis and hyperpigmentation
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 900-910, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres23.1717_12.5.900 Original Article Piceatannol-rich extract from Passiflora edulis Sims seeds attenuates morphological differentiation through the reduction of MITF mRNA expression and F-actin polymerization in UVB-induced hyperpigmented B16F10 cells [El extracto rico en piceatannol de las semillas de Passiflora edulis Sims atenúa la … Continue reading Piceatannol-rich extract from Passiflora edulis and hyperpigmentation
Immunostimulatory effect of a nature-derived capsule
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 892-899, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres23.1751_12.5.892 Original Article Potential effects of Linh Loc Son hard capsule – a Vietnamese herbal combination in immunodeficiency induced by cyclophosphamide on mice [Efectos potenciales de la cápsula dura Linh Loc Son, una combinación de hierbas vietnamitas en la inmunodeficiencia inducida por … Continue reading Immunostimulatory effect of a nature-derived capsule
Epidermal growth factor receptor mutant inhibitors as NSCLC drugs
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 881-891, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres23.1740_12.5.881 Original Article Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs [Inhibidor del receptor del factor de crecimiento epidérmico mutante T790M-L858R-V948R de la hoja de Calophyllum inophyllum L. como posible fármaco … Continue reading Epidermal growth factor receptor mutant inhibitors as NSCLC drugs

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio